Pomalidomide and Dexamethasone

DRUG3 trials

Sponsors

Fondazione IRCCS Policlinico San Matteo di Pavia, Celgene, National University Hospital, Singapore

Conditions

Multiple MyelomaPrimary Amyloidosis of Light Chain TypeRelapse After Use of Lenalidomide and Bortezomib

Phase 2

Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis

CompletedNCT01510613

Fondazione IRCCS Policlinico San Matteo di PaviaPrimary Amyloidosis of Light Chain Type

Start: 2012-02-29End: 2016-12-31Updated: 2018-03-12

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

CompletedNCT02045017

CelgeneMultiple Myeloma

Start: 2014-02-28End: 2021-07-28Updated: 2021-08-27

Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib

National University Hospital, SingaporeMultiple Myeloma, Relapse After Use of Lenalidomide and Bortezomib

Start: 2014-11-30End: 2018-11-30Target: 100Updated: 2018-05-17

Related Papers

Randomized Trial Comparing Pomalidomide, Bortezomib, and Dexamethasone (PVd) Versus Bortezomib and Dexamethasone（Vd） in NDMM with Renal Impairment（RI）

Blood2021-11-05

Large-Scale Analysis of Relapsed/Refractory Multiple Myeloma Genome Reveals Increased Prevalence of High-Risk Molecular Features and Oncogenic Drivers

Blood2019-11-13

PB2117 POMALIDOMIDE PLUS LOW‐DEXAMETHASONE TREATMENT FOR ≥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MM‐013 PHASE 2 STUDY

HemaSphere2019-06-01

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

Blood2017-01-2790 citations

Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Blood2016-12-021 citations

Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

Blood2015-12-036 citations

MM-013: An ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI) including patients (pts) undergoing hemodialysis.

Journal of Clinical Oncology2014-05-205 citations

High-Dose Pomalidomide and Dexamethasone Induce Rapid Responses In Patients With AL Amyloidosis Exposed To Alkylators, Immune Modulatory Drugs, and Proteasome Inhibitors

Blood2013-11-156 citations